Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas

Journal of Pathology

Volumn 198, Issue 2, 2002, Pages 142-156

  Gorgoulis, Vassilis G ^a,f   Zacharatos, Panayotis ^a   Mariatos, George ^a   Kotsinas, Athanassios ^a   Bouda, Martha ^a   Kletsas, Dimitris ^b   Asimacopoulos, Panayiotis J ^a,c   Agnantis, Niki ^d   Kittas, Christos ^a   Papavassiliou, Athanasios G ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF IOANNINA   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f NONE   (Greece)

Author keywords

Apoptosis; CBP; E2F 1; Lung cancer; MDM2; p53; pRb; Prognosis; Proliferation

Indexed keywords

DNA; GROWTH PROMOTOR; MESSENGER RNA; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE CONTROL; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REGRESSION ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL DIVISION; CREB-BINDING PROTEIN; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DNA, NEOPLASM; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036773376     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1121     Document Type: Article

References (79)

1. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev 1998; 12: 2245-2262.
2. Black RA, Azizkhan-Clifford J. Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 1999; 237: 281-302.
3. Hesketh R. E2F1 The Oncogene and Tumor Suppressor Gene: Factsbook (2nd edn). Academic Press: London, 1997; 425-427.
4. Huber HE, Goodhart PJ, Huang PS. Retinoblastoma protein reverses DNA bending by transcription factor E2F. J Biol Chem 1994; 269: 6999-7005.
5. Bandara LR, Lam W-FE, Sorensen TS, Zamanian M, Girling R, La Thangue NB. DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J 1994; 13: 3104-3114.
6. Helin K, Wu C-L, Fattaey A, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev 1993; 7: 1850-1861.
7. Muller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 2000; 1470: M1-M12.
8. Hagemeier C, Cook A, Kouzarides T. The retinoblastoma protein binds E2F residues required for activation in vivo and TBP binding in vitro. Nucleic Acid Res 1993; 21: 4998-5504.
9. Pearson A, Greenblatt J. Modular organization of the E2F1 activation domain and its interaction with general transcription factors TBP and TFIIH. Oncogene 1997; 15: 2643-2658.
10. Martin K, Trouche D, Hagemeier C, Sorensen TS, Lathangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by mdm2 oncoprotein. Nature 1995; 375: 691-694.
11. Lee CW, Sorensen TS, Shikama N, Lathangue NB. Functional interplay between p53 and E2F through co-activator p300. Oncogene 1998; 16: 2695-2710.
12. Ross JF, Liu X, Dynlacht BD. Mechanism of transcriptional repression of E2F by the retinoblastoma tumor suppressor protein. Mol Cell 1999; 3: 195-205.
13. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits historic deacetylase to repress transcription. Nature 1998; 391: 597-601.
14. Neuman E, Flemington E, Sellers W, Kaelin W. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994; 14: 6607-6615.
15. Bates S, Phillips AC, et al. P14ARF links the tumor suppressors RB and p53. Nature 1998; 395: 124-125.
16. O'Connor DJ, Lam EW, Griffin S, et al. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 1995; 14: 6184-6192.
17. Yamasaki L. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1999; 1423: M9-M15.
18. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-2409.
19. Gala S, Marreiros A, Stewart GJ, Williamson P. Overexpression of E2F-1 leads to cytokine-independent proliferation and survival in the hematopoietic cell line BaF-B03. Blood 2001; 97: 227-234.
20. Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJP. E2F1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines. Cancer Res 2000; 60: 5972-5976.
21. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823-12827.
22. Yamazaki L, Jaks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tumor atrophy in mice lacking E2F1. Cell 1996; 85: 537-548.
23. Hunt KK, Deng J, Liu T-J, et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997; 57: 4722-4726.
24. Field S, Tsai F-Y, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
25. Phillips AC, Bates S, Ryan KM, Helin K, Vousden H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 1997; 11: 1853-1863.
26. Shan B, Durfee T, Lee W-H. Disruption of Rb/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc Natl Acad Sci USA 1996; 93: 679-684.
27. Krek W, Xu G, Livingston D. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995; 83: 1149-1158.
28. Shan B, Lee W-H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14: 8166-8173.
29. Zhang SY, Liu SC, Al-Saleem LF, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 2000; 9: 395-401.
30. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11: 457-463.
31. Rabbani F, Richon VM, Orlow I, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999; 91: 874-881.
32. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999; 81: 535-538.
33. Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer 1998; 79: 294-299.
34. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-1687.
35. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLC). Mol Med 2000; 6: 208-237.
36. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Alterations of the p16-pRb pathway and the chromosome locus 9p2l-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 1998; 153: 1749-1765.
37. Davis LG, Dibner MD, Battey JF. Basic Methods in Molecular Biology. Elsevier Science: New York, 1986;
38. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Deregulated expression of c-mos in non-small cell lung carcinomas (NSCLCs). Relationship with p53 status, genomic instability and tumor kinetics. Cancer Res 2001; 61: 538-549.
39. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000; 6: 623-644.
40. Snowden AW, Perkins ND. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem Pharmacol 1998; 55: 1947-1954.
41. Trouche D, Cook A, Kouzarides T. The CBP co-activator stimulates E2F1/Dp1 activity. Nucleic Acid Res 1996; 24: 4139-4145.
42. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998; 1378: F21-F59.
43. Michelland S, Gazzeri S, Brambilla E, Robert-Nicoud M. Comparison of chromosomal imbalances in neuroendocrine and non-small-cell lung carcinomas. Cancer Genet Cytogenet 1999; 114: 22-30.
44. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 2000; 82: 65-73.
45. Luk C, Tsao M, Bayani J, Shepherd F, Squire JA. Molecular cytogenic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001; 125: 87-99.
46. Hsiao KM, McMahon SL, Farhham PJ. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 1994; 13: 1526-1537.
47. Hofmann F, Martelli F, Livingston DM, Wang Z. The retinoblastoma gene product protects E2F1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 1996; 10: 2949-2959.
48. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J 1999; 18: 1559-1570.
49. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000; 19: 662-671.
50. Stiegler P, Kasten M, Giordano A. The family of cell cycle regulatory factors. J Cell Biochem (Suppl) 1998; 31: 30-36.
51. Lin S-Y, Black AR, Kostic A, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle regulated association of E2F1 and SP1 is related to their functional interaction. Mol Cell Biol 1996; 16: 1668-1675.
52. Udvadia A, Rogers KT, Higgins PDR, et al. Sp1 binds promoter elements regulated by the Rb protein and Sp1 stimulated transcription is stimulated by Rb coexpression. Proc Natl Acad Sci U S A 1993; 90: 3265-3269.
53. Kim S-J, Wagner S, Liu F, O'Reilly MA, Robbins PD, Green MR. Retinoblastoma gene product activates expression of the human TGF-β2 gene through transactivation factor ATF-2. Nature 1992; 358: 331-334.
54. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358: 259-261.
55. Sparato V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998; 77: 448-455.
56. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R, Beijersbergen RL. Degradation of E2F by the ubiquitin-proteasome pathway, regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev 1996; 10: 2960-2970.
57. INK4A and alterations of the 9p21-23 chromosome region in non-small cell lung carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 2000; 89: 133-141.
58. Leone G, DeGregori J, Yan Z, et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S-phase. Genes Dev 1998; 12: 2120-2130.
59. Martelli F, Livingston DM. Regulation of endogenous E2F1 stability by the retinoblastoma family proteins. Proc Natl Acad Sci USA 1999; 96: 2858-2863.
60. Nakamura T, Monden Y, Kawashima K, Naruke T, Nishimura S. Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 in human cancers. Jpn J Cancer Res 1996; 87: 1204-1209.
61. Pepper DS, Keblusek P, Helin K, Toebes M, van der Eb AJ, Zantema A. Phosphorylation of a specific cdk site in E2F1 affects its electrophoretic mobility and promotes pRb-binding in vitro. Oncogene 1995; 10: 39-48.
62. Dynlacht BD, Flores O, Lees JA, Harlow E, Zhu L. Specific regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev 1994; 8: 1772-1786.
63. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG, Jr Livingston DM. Negative regulation of the growth-promoting transcription factor E2F1 by a stably bound cyclin A-dependent protein kinase. Cell 1994; 78: 161-172.
64. Qin XQ, Livingston DM, Kaelin WG, Jr Adams PD. Deregulated transcription factor E2F1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918-10922.
65. Kowalik TF, DeGregori J, Sewartz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995; 69: 2491-2500.
66. Fueyo J, Gornez-Manzano C, Yung WK, et al. Overexpression of E2F1 in glioma trigger apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998; 4: 685-690.
67. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
68. Zhang Y, Xiong Y, Yarbrourgh WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
69. Hsieh J-K, Chan FSG, O'Connor DJ, Mittnacht S, Zhong S, Lu X. Rb regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 1999; 3: 181-193.
70. Yap DB, Hsieh JK, Chan FS, Lu X. Mdm2: a bridge over the two tumor suppressors, p53 and Rb. Oncogene 1999; 18: 7681-7689.
71. Loughran O, La Thangue NB. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 2000; 20: 2186-2197.
72. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 1997; 11: 1853-1863.
73. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH. E2F1 potentiates cell death by blocking anti-apoptotic signaling pathways. Mol Cell 1999; 4: 771-781.
74. Stiewe T, Putzer BM. Role of p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26: 464-469.
75. Pauvlovich AG, Toczyski DP, Hartwell LH. When checkpoints fail. Cell 1997; 88: 315-321.
76. Lukas S, Sorensen CS, Kramer E, et al. Accumulation of cyclinB1 requires E2F and cyclin A-dependent rearrangement of the anaphase-promoting complex. Nature 1999; 401: 815-818.
77. Morgenbesser SD, Williams BO, Jacks T, Depinho RA. P53 dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371: 72-74.
78. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-711.
79. Pan H, Yin C, Dyson NJ, Harlow E, Yamasaki L, van Dyke T. Key roles for E2F1 in p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 1998; 2: 283-292.